Literature DB >> 11123845

Statins in children: what do we know and what do we need to do?

D M Black1.   

Abstract

Children have been tested and treated for hypercholesterolemia for more than 30 years. Although most treatment regimens have been limited to dietary intervention, statin use is increasing. Statins have been used in children since 1987, but published sources have only reported on small numbers of children with severe hypercholesterolemia. The available data indicates that statins can be useful and well tolerated. New data will be available in the next few years that will lead to the wider use of these drugs. Although statin drugs have proven to be safe in the adult population, physicians will be obliged to follow pediatric patients closely when these agents are widely used in the first few years. The use of highly effective safe drugs such as statins will allow for the assessment of the best time to initiate therapy in younger populations and what benefits may be found over the long term.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123845     DOI: 10.1007/s11883-001-0007-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  39 in total

1.  Simvastatin use in children.

Authors:  J Ducobu; D Brasseur; J M Chaudron; J P Deslypere; C Harvengt; E Muls; M Thomson
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

2.  Treatment of familial hypercholesterolemia with drugs in children.

Authors:  E A Stein
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

3.  Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood.

Authors:  C Stefanutti; G Lucani; A Vivenzio; S Di Giacomo
Journal:  Drugs Exp Clin Res       Date:  1999

Review 4.  Pharmacologic and surgical treatment of dyslipidemic children and adolescents.

Authors:  J M Hoeg
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

5.  Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.

Authors:  J E Coleman; A R Watson
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

6.  Security and maximal tolerated doses of fluvastatin in pediatric cancer patients.

Authors:  E López-Aguilar; A C Sepúlveda-Vildósola; H Rivera-Márquez; F Cerecedo-Diaz; M Valdez-Sánchez; M A Villasis-Keever
Journal:  Arch Med Res       Date:  1999 Mar-Apr       Impact factor: 2.235

7.  An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.

Authors:  D M Black; R G Bakker-Arkema; J W Nawrocki
Journal:  Arch Intern Med       Date:  1998-03-23

8.  The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.

Authors:  D L Sprecher; J M Hoeg; E J Schaefer; L A Zech; R E Gregg; E Lakatos; H B Brewer
Journal:  Metabolism       Date:  1985-03       Impact factor: 8.694

9.  Safety and efficacy of treatment of pediatric cholesteryl ester storage disease with lovastatin.

Authors:  C J Glueck; P Lichtenstein; T Tracy; J Speirs
Journal:  Pediatr Res       Date:  1992-11       Impact factor: 3.756

10.  Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia.

Authors:  L Laue; J M Hoeg; K Barnes; J L Ross; D L Loriaux; G P Chrousos
Journal:  Horm Res       Date:  1988
View more
  5 in total

Review 1.  A general assessment of the safety of HMG CoA reductase inhibitors (statins).

Authors:  Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 2.  Pharmacoeconomics of lipid-lowering drugs.

Authors:  Dean G Smith
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

3.  Prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes in Austria.

Authors:  Claudia Steigleder-Schweiger; Birgit Rami-Merhar; Thomas Waldhör; Elke Fröhlich-Reiterer; Ines Schwarz; Maria Fritsch; Martin Borkenstein; Edith Schober
Journal:  Eur J Pediatr       Date:  2012-03-16       Impact factor: 3.183

Review 4.  Should pediatric patients with hyperlipidemia receive drug therapy?

Authors:  Deepak Bhatnagar
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report.

Authors:  Elaine C Tsai; Judy A Brown; Megan Y Veldee; Gregory J Anderson; Alan Chait; John D Brunzell
Journal:  BMC Pregnancy Childbirth       Date:  2004-12-20       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.